What’s New in Testicular Cancer Research?
Important research into testicular cancer is being done around the world. Each year, scientists find out more about what causes the disease, how to prevent it, how to detect it earlier, and how to improve treatment.
Biomarkers for early detection
Doctors use blood tests to help find testicular cancer, but the usual markers (AFP, hCG, LDH) don’t always work well. Researchers are studying new biomarkers to make diagnosis more accurate. One of the most promising is microRNA-371a-3p (miR-371a-3p), a small molecule in the blood that may be much better at detecting cancer. Scientists are also studying circulating tumor DNA (ctDNA) and exosomes (tiny particles released by cells) to see if they can help find cancer earlier and track treatment progress.
Genomic research
Testicular cancer happens when certain genes change (mutate) and cause cells to grow out of control. Researchers have found that gene changes in KIT and KRAS help tumors grow. Changes in TP53 and CCND1 may make cancer harder to treat. Many testicular tumors have extra copies of chromosome 12p, which plays a big role in cancer growth. Scientists are also studying stem-like cancer cells that may help tumors survive chemotherapy. Understanding these cells could lead to better treatments and a lower risk of cancer returning.
Immunotherapy and targeted therapy
For testicular cancer that doesn’t respond to treatment or comes back, researchers are testing checkpoint inhibitors (PD-1/PD-L1 inhibitors). These drugs help the immune system fight cancer. Another possible treatment is CAR-T cell therapy, which changes a patient’s own immune cells to attack cancer cells. This approach is still in early research but may offer new hope for tough-to-treat cases.
Chemotherapy
Scientists are working on making chemotherapy safer while keeping it effective. The common drug cisplatin works well but can cause serious side effects like hearing loss and kidney damage. Researchers are testing new drug combinations to reduce these risks. Doctors are also studying de-escalation therapy, or using lower doses of chemotherapy to see if it still cures cancer while reducing long-term health problems.
Fertility preservation
Since testicular cancer treatments can affect fertility, doctors recommend sperm banking before starting treatment. Scientists are also studying stem cell therapy to see if it can help with fertility in the future.
Survivorship
After treatment, some survivors face health challenges, like heart problems, secondary cancers, or mental health struggles. Research is focusing on helping survivors live healthier, longer lives.
- Written by
- References
Developed by the American Cancer Society medical and editorial content team with medical review and contribution by the American Society of Clinical Oncology (ASCO).
Dieckmann, K. P., Radtke, A., Geczi, L., Matthies, C., Anheuser, P., Eckardt, U., ... & Belge, G. (2019). Serum levels of microRNA miR-371a-3p: A highly sensitive and specific new biomarker for germ cell tumors in adults. European Urology, 75(3), 447-456. DOI: 10.1016/j.eururo.2018.10.011
Murray, M. J., Huddart, R. A., Coleman, N. (2016). The present and future of serum diagnostic tests for testicular germ cell tumours. Nature Reviews Urology, 13, 715–725. DOI: 10.1038/nrurol.2016.185
Gillis, A. J. M., Rijlaarsdam, M. A., Eini, R., Dorssers, L. C. J., & Looijenga, L. H. J. (2013). Molecular Determinants of Testicular Germ Cell Tumors. Nature Reviews Cancer, 13(7), 482–495. DOI: 10.1038/nrc3563
Nathanson, K. L., Kanetsky, P. A., Hawes, R., Vaughn, D. J., Letrero, R., Tucker, K., & Greene, M. H. (2005). Candidate gene association study of testicular cancer. Human Molecular Genetics, 14(20), 2703–2709. DOI: 10.1093/hmg/ddi301
Taylor-Weiner, A., Zack, T., O’Donnell, E., Guerriero, J. L., Bernard, B., Reddy, A., ... & Getz, G. (2016). Genomic evolution and chemoresistance in germ cell tumors. Nature Genetics, 48, 768–776. DOI: 10.1038/ng.3585
Feldman, D. R., Lorch, A., Kramar, A., Albany, C., Einhorn, L. H., Williams, S. D., ... & Kollmannsberger, C. (2022). Clinical advances in the management of testicular cancer. Journal of Clinical Oncology, 40(4), 401-418. DOI: 10.1200/JCO.21.01531
Chovanec, M., Cheng, L., Michl, U., Fankhauser, C. D., Rava, M., Necchi, A., ... & Kollmannsberger, C. (2021). Emerging molecular targets for the treatment of testicular germ cell tumors. Nature Reviews Urology, 18, 417–433. DOI: 10.1038/s41585-021-00468-9
Lobo, J., Costa, A. L., Cantante, M., Guimar?es, R., Lopes, P., Antunes, L., ... & Henrique, R. (2018). Circulating miR-371a-3p and miR-367-3p as potential biomarkers for testicular germ cell tumors. Cancers, 10(8), 273. DOI: 10.3390/cancers10080273
Last Revised: August 10, 2025
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
American Cancer Society Emails
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.